Albert Mwafongo1, Kondwani Nkanaunena, Yu Zheng, Evelyn Hogg, Wadzanai Samaneka, Lloyd Mulenga, Abraham Siika, Judith Currier, Shahin Lockman, Michael D Hughes, Mina Hosseinipour. 1. aUniversity of North Carolina Project, Kamuzu Central Hospital, Lilongwe bJohns Hopkins Project, Queen Elizabeth Central Hospital, Blantyre, Malawi cHarvard School of Public Health, Boston, Massachusetts dSocial & Scientific Systems, Inc., Silver Spring, Maryland, USA eUZ-UCSF Collaborative Research Programme, Harare, Zimbabwe fCenter for Infectious Disease Research, Lusaka, Zambia gMoi University (College of Health Sciences), Eldoret, Kenya hUniversity of California, Los Angeles, Los Angeles, California iBrigham and Women's Hospital, Boston, Massachusetts jUniversity of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Abstract
OBJECTIVES:Tenofovir disoproxil fumarate (TDF) has been associated with renal insufficiency. Co-administration with boosted protease inhibitors, which increases its exposure, may further increase the risk of renal insufficiency. METHODS: We compared the incidence of renal events among women taking TDF co-administered withlopinavir/ritonavir (LPV/r) versus those co-administering TDF with nevirapine (NVP). Renal events were defined as a confirmed drop in creatinine clearance associated with a serum creatinine grade 2 or higher, or that leading to treatment modification. RESULTS: Overall, 741 HIV-infected women were enrolled into the study. Of these, 24 (3.2%) had reportable renal events (18 in LPV/r arm, six in NVP arm). In multivariate analysis, renal events were significantly associated with the LPV/r arm [odds ratio (OR) 3.12, 95% confidence interval (CI) 1.21, 8.05; P = 0.019], baseline HIV-1 RNA (OR 2.65, 95% CI 1.23, 5.69 per 1 log10 copies/ml higher; P = 0.013) and baseline creatinine clearance (OR 0.83, 95% CI 0.70-0.98 per 10 ml/min higher; P = 0.030). In multivariate analysis evaluating renal events requiring treatment modification, only baseline HIV-1 RNA and creatinine clearance were significantly associated (OR 4.41, 95% CI 1.65, 11.78 per 1 log10 copies/ml higher; P = 0.003 and OR 0.80, 95% CI 0.64, 0.99 per 10 ml/min higher; P = 0.040, respectively). CONCLUSION: The rates of renal events were relatively low in the two treatment arms. However, patients taking TDF co-administered with LPV/r had significantly more renal events compared to those co-administered with NVP. Furthermore, higher baseline HIV RNA and lower creatinine clearance were associated with the development of renal insufficiency requiring treatment modification.
RCT Entities:
OBJECTIVES:Tenofovir disoproxil fumarate (TDF) has been associated with renal insufficiency. Co-administration with boosted protease inhibitors, which increases its exposure, may further increase the risk of renal insufficiency. METHODS: We compared the incidence of renal events among women taking TDF co-administered with lopinavir/ritonavir (LPV/r) versus those co-administering TDF with nevirapine (NVP). Renal events were defined as a confirmed drop in creatinine clearance associated with a serum creatinine grade 2 or higher, or that leading to treatment modification. RESULTS: Overall, 741 HIV-infectedwomen were enrolled into the study. Of these, 24 (3.2%) had reportable renal events (18 in LPV/r arm, six in NVP arm). In multivariate analysis, renal events were significantly associated with the LPV/r arm [odds ratio (OR) 3.12, 95% confidence interval (CI) 1.21, 8.05; P = 0.019], baseline HIV-1 RNA (OR 2.65, 95% CI 1.23, 5.69 per 1 log10 copies/ml higher; P = 0.013) and baseline creatinine clearance (OR 0.83, 95% CI 0.70-0.98 per 10 ml/min higher; P = 0.030). In multivariate analysis evaluating renal events requiring treatment modification, only baseline HIV-1 RNA and creatinine clearance were significantly associated (OR 4.41, 95% CI 1.65, 11.78 per 1 log10 copies/ml higher; P = 0.003 and OR 0.80, 95% CI 0.64, 0.99 per 10 ml/min higher; P = 0.040, respectively). CONCLUSION: The rates of renal events were relatively low in the two treatment arms. However, patients taking TDF co-administered with LPV/r had significantly more renal events compared to those co-administered with NVP. Furthermore, higher baseline HIV RNA and lower creatinine clearance were associated with the development of renal insufficiency requiring treatment modification.
Authors: Hana M El Sahly; Larry Teeter; Teddy Zerai; Roberto A Andrade; Cesar Munoz; Calista Nnabuife; Rodney Hunter Journal: AIDS Date: 2006-03-21 Impact factor: 4.177
Authors: Anthony E Zimmermann; Thomas Pizzoferrato; John Bedford; Anne Morris; Robert Hoffman; Gregory Braden Journal: Clin Infect Dis Date: 2005-12-08 Impact factor: 9.079
Authors: Vasantha Jotwani; Rebecca Scherzer; Michelle M Estrella; Lisa P Jacobson; Mallory D Witt; Frank Palella; Bernard Macatangay; Michael Bennett; Chirag R Parikh; Joachim H Ix; Michael Shlipak Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Vasantha Jotwani; Rebecca Scherzer; Michelle M Estrella; Lisa P Jacobson; Mallory D Witt; Frank J Palella; Bernard Macatangay; Michael Bennett; Chirag R Parikh; Joachim H Ix; Michael G Shlipak Journal: Am J Kidney Dis Date: 2016-06-08 Impact factor: 8.860
Authors: Reneé De Waal; Karen Cohen; Matthew P Fox; Kathryn Stinson; Gary Maartens; Andrew Boulle; Ehimario U Igumbor; Mary-Ann Davies Journal: J Int AIDS Soc Date: 2017-04-10 Impact factor: 5.396
Authors: Herry Mapesi; Aneth V Kalinjuma; Alphonce Ngerecha; Fabian Franzeck; Christoph Hatz; Marcel Tanner; Michael Mayr; Hansjakob Furrer; Manuel Battegay; Emilio Letang; Maja Weisser; Tracy R Glass Journal: Open Forum Infect Dis Date: 2018-04-06 Impact factor: 3.835
Authors: Herry Mapesi; James Okuma; Fabian Franzeck; Herieth Ismael Wilson; Elizabeth Senkoro; Theonestina Byakuzana; Robert Ndege; Fiona Vanobberghen; Tracy Renée Glass; Manuel Battegay; Maja Weisser; Daniel Henry Paris Journal: PLoS One Date: 2021-12-15 Impact factor: 3.240